CD8A and non-small cell lung carcinoma: The mIF-based profiling of a cohort of 64 NSCLC samples with a 6-color CD4, CD8, CD20, FoxP3, inducible T cell costimulator (ICOS), and T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) panel further substantiated these findings, revealing a heightened stromal CD4+ T cell presence in MYH11+αSMA+ CAF-high tumors, without comparable changes in other T or B cell subsets (Figures S6C and S6D).